Amicus Therapeutics
AMICUS THERAPEUTICS INC (Form: 8-K, Received: 04/28/2017 12:02:52)

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 28, 2017

 

AMICUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33497

 

71-0869350

(State or other Jurisdiction of Incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

1 Cedar Brook Drive, Cranbury, NJ

 

08512

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (609) 662-2000

 

 

(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 



 

Item 8.01. Other Events.

 

On April 28, 2017, members of the management team of Amicus Therapeutics, Inc. (the “Company”) will present posters related to its SD-101 program at the 76 th  Annual Meeting of the Society for Investigative Dermatology in Portland, Oregon. A copy of these posters is attached hereto as Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:  The Exhibit Index annexed hereto is incorporated herein by reference.

 

Exhibit
No.

 

Description

99.1

 

Posters dated April 28, 2017 titled “Investigation of the Absorption of Allantoin From SD-101 in In Vitro Skin Models to Support Wound Healing” and “Characteristics of Patients With Epidermolysis Bullosa in the Phase 3 ESSENCE Study of SD-101.”

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

AMICUS THERAPEUTICS, INC.

 

 

Date: April 28, 2017

By:

/s/ ELLEN S. ROSENBERG

 

Name:

Ellen S. Rosenberg

 

Title:

General Counsel and Corporate Secretary

 

3


Exhibit 99.1

 

701 Investigation oftheAbsorption ofAllantoinFromSD-101in InVitroSkinModelstoSupportWoundHealing Paller AS1, Nardi R2, Do H3, Reha A3, Viereck C3, Lagast H3, Gault J2, Castelli JP3, Barth JA3 1Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Scioderm - An Amicus Therapeutics Company, Durham, NC, USA; 3Amicus Therapeutics, Inc., Cranbury, NJ, USA Table 1. Total Skin Absorption of Allantoin (µg) Over 48 hours From a Single Application INTRODUCTION Allantoin is a heterocyclic organic compound that has been investigated in wound healing, using formulations with minimal or unknown dermal penetration properties1,2 SD-101 is a novel, proprietary, topical, allantoin-containing cream in development for the daily treatment of wounds caused by all major types of epidermolysis bullosa.3 SD-101 has received Breakthrough Therapy designation from the US Food and Drug Administration4 RESULTS • • In the SD-101 formulation:    There was evidence of skin absorption of allantoin in all models (Figures 2 and 3 and Table 1) Skin absorption of allantoin was lowest in intact human skin (Figure 3 and Table 1) Skin absorption increased with higher concentrations of allantoin in the dermis-only human model; uptake between the barrier-free and dermis-only human models was similar Allantoin skin absorption in the human skin models was slow (8 hours for dermis-only), suggesting a long skin-exposure time (Figures 2C and 2D) • Epidermolysis bullosa is a rare genetic disorder typically manifesting at birth as skin blistering/erosion and, in some cases, the epithelial lining of other organs, in response to minimal friction/trauma5 In a phase 2b study, patients with epidermolysis bullosa treated with SD-101 6% (SD-101 with 6% allantoin) demonstrated a higher rate of wound closure over a 1-month period than placebo-treated patients3 SD-101 6% is currently in phase 3 clinical development Figure 2. Skin Absorption of Allantoin (0.5% to 9%), a Component of SD-101, Within 40 Hours in Various Skin Models In vitro human cadaver and porcine models are recognized valuable tools to assess the skin absorption and to determine the pharmacokinetics of topically applied drugs6-8 Separate preclinical studies of SD-101 with allantoin concentrations of up to 9% indicated no systemic absorption9 • Data are represented as mean ± standard error from 3 replicates per formulation as total mass (µg). aBarrier-free study was conducted over 24 hours. OBJECTIVE To investigate the skin absorption of 0.5%, 1.5%, 3%, 6%, and 9% concentrations of allantoin, the active ingredient in the SD-101 formulation, in skin models that mimic intact, broken, or blistered human skin CONCLUSIONS • METHODS Models • The skin absorption of 0.5%, 1.5%, 3%, 6%, and 9% concentrations of allantoin, the active ingredient in the SD-101 formulation, was investigated in 5 in vitro models: Barrier-free to simulate delivery directly to the capillary bed Unabraded porcine skin Abraded porcine skin to simulate compromised skin Intact (full thickness) human skin Dermis-only human to mimic loss of skin barrier function due to broken skin REFERENCES Becker LC et al. Int J Toxicol. 2010;29(suppl 2):84S-97S. Xi H et al. J Bacteriol. 2000;182(19):5332-5341. Paller A et al. Presented at: 42nd Annual Meeting of the Society for Pediatric Dermatology; July 14-17, 2016; Minneapolis, MN. Aggarwal SR. Nature Biotechnol. 2014;32(4):323-330. El Hachem M et al. Orphanet J Rare Dis. 2014;9:76. Franz TJ. J Invest Derm. 1975;64(3):190-195. Franz TJ. In: Simon GA et al, eds. Skin: Drug Application and Evaluation of Environmental Hazards. Basel, Switzerland: Karger; 1978:58-68. Current Problems in Dermatology; vol 7. Schmook FP et al. Int J Pharm. 2001;215(1-2):51-56. Amicus Therapeutics Inc. Investigators Brochure, Data on File. Franz TJ, Lehman PA. J Invest Dermatol. 1990;94:525. Kim KW et al. Opt Express. 2012;20(9):9476-9484. Skin Cadaver Preparation • All human and porcine cadaver trunk skin without obvious signs of skin disease was stored at less than -70°C within 24 hours of death. On experiment day, the bagged tissue was thawed in 37°C water and rinsed to remove any adherent blood or material from the surface. Approximately 75% of the dermis was removed by dermatome or scalpel visually 1. 2. 3. Donor skin was cut into smaller sections and fitted on 0.8-cm2 Franz diffusion cells. The diffusion cells were then placed between the epidermal chamber (route of drug application) and the dermal chamber, which was filled with magnetically stirred phosphate-buffered saline, and sampled at selected time points (Figure 1) The permeability to tritiated water was determined prior to experimentation to assure skin integrity10 4. 5. 6. 7. 8. 9. 10. 11. Figure 1. Schematic of the Skin Franz Cell Diffusion System11 Franz cell diffusion system ACKNOWLEDGMENTS Third-party medical writing assistance was provided by ApotheCom and was supported by Amicus Therapeutics, Inc. Skin port Data are represented as mean from 3 replicates per formulation as μg/cm2/hour. aOnly 3% allantoin was tested in the unabraded model. Figure 3. Total Skin Absorption of Allantoin Over 48 Hours From a Single Application DISCLOSURES Intact (full thickness) human Conflicts of Interest AP is an investigator and a consultant for Amicus Therapeutics. RN and JG are employees of Scioderm - An Amicus Therapeutics Company and own stock in Amicus Therapeutics. HD, AR, CV, HL, JPC, and JAB are employees of and own stock in Amicus Therapeutics. 3000 Barrier-free Reprinted with permission from Kim KW et al. Opt Express. 2012;20(9):9476-9484. Application • Concentrations of SD-101 or vehicle (SD-101 minus active ingredient) were tested on 3 sections from 6 different skin donors (3 cadaver, 3 porcine) that were mounted in chambers designed to maintain skin at a temperature and humidity matching typical in vivo conditions Each test product was applied at a target dose of 100 μL/cm2 using a calibrated positive displacement pipette and then covered with 3 layers of medical-grade gauze Sampling • After SD-101 application, skin absorption (total absorption, rate of absorption, and skin content) was measured by monitoring the rate of appearance of drug in the solution bathing the inner surface of the skin Samples were collected roughly 2, 4, 8, 12, 24, 32, and 48 hours after application and analyzed for allantoin using high-performance liquid chromatography with ultraviolet and mass spectrometry detection Data are represented as mean ± standard error from 3 replicates per formulation as total mass (μg). http://bit.ly/2958kHL Supported by Amicus Therapeutics, Inc. Presented at the 76th Annual Meeting of the Society for Investigative Dermatology; April 26-29, 2017; Portland, OR, USA Flux (µg/cm2/hour) Flux (µg/cm2/hour) Flux (µg/cm2/hour) Flux (µg/cm2/hour) Total Penetration as Mass (µg) 3500 Abraded porcine Dermis-only human 2500 2000 1500 1000 500 0 0.5% 1.5% 3% 6% 9% Allantoin Concentration Stratum corneum Excised skin Epidermis Dermis Sampling 2 32oC Circula ng Replacing water port Magne c s rrer 3 1 • Allantoin, the active ingredient of the SD-101 formulation, is absorbed by the intact stratum corneum, or skin, which may reduce wound formation • In the SD-101 formulation, allantoin skin absorption in the intact (full thickness) human model was slow, suggesting a long skin-exposure time • In damaged skin models that provide insight into the absorption of wounded skin, absorption of allantoin increased significantly • Substantial skin absorption of 6% allantoin occurred over several hours in the intact full-thickness human skin model, suggesting that SD-101’s formulation, with higher concentrations of allantoin than are currently used, is capable of penetrating human skin • In summary, these findings further support the therapeutic investigation of SD-101 6% to treat wounds in a clinical setting and the ongoing phase 3 ESSENCE trial in epidermolysis bullosa (NCT02384460) A. Barrier-Free 1200 1000 800 600 400 200 0 0 2 4 6 8 10 12 14 16 18 Time (hours) B. Abraded and Unabradeda Porcine 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 0 10 20 30 40 Time (hours) C. Intact (full thickness) Human 1.8 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 0 10 20 30 40 Time (hours) D. Dermis-Only Human 225 200 175 150 125 100 75 50 25 0 0 10 20 30 40 Time (hours) 0.5% Allantoin 3% Allantoin 9% Allantoin 1.5% Allantoin 6% Allantoin 3% Allantoin (unabraded only) Skin Model Allantoin Concentration 0.5% 1.5% 3% 6% 9% Intact (full thickness) human 12.05 ± 1.88 13.23 ± 5.61 32.04 ± 11.42 41.57 ± 8.43 22.74 ± 12.15 Abraded porcine 38.80 ± 18.34 68.91 ± 31.01 95.74 ± 25.55 109.52 ± 39.31 103.70 ± 34.23 Barrier-freea 196.48 ± 45.30 792.25 ± 39.83 1399.49 ± 205.99 1348.30 ± 201.39 2294.42 ± 552.35 Dermis-only human 412.60 ± 96.30 910.51 ± 73.99 1434.19 ± 95.71 1990.40 ± 167.34 2718.74 ± 548.33 Unabraded porcine Not tested Not tested 38.64 ± 15.24 Not tested Not tested

 


696 CharacteristicsofPatientsWithEpidermolysisBullosa inthePhase3ESSENCEStudyofSD-101 Browning J1, Bruckner A2, Cornwall R3, Lugo-Somolinos A4, Paller A5, Lagast H6, Reha A6, Gault J7, Lenon W7, Reklis L7, Lazauskas R6, Nardi R7 1Texas Dermatology & Laser Specialists, San Antonio, TX, USA; 2University of Colorado Denver, Aurora, CO, USA; 3Cincinnati Children’s Hospital, Cincinnati, OH, USA; 4University of North Carolina School of Medicine, Chapel Hill, NC, USA; 5Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 6Amicus Therapeutics, Inc., Cranbury, NJ, USA; 7Scioderm - An Amicus Therapeutics Company, Durham, NC, USA Assessments • Patients enrolled in ESSENCE demonstrated a substantial burden of pain at baseline (Table 2) INTRODUCTION Epidermolysis bullosa is a rare, often severe genetic disorder characterized by mechanical fragility and blistering or erosion of the skin, mucosa, or epithelial lining of other organs, in response to little or no apparent trauma1 • During patient visits, the following evaluations are performed: Table 2. Baseline Pain Scores  Baseline-selected target wound closure evaluation using ARANZ SilhouetteStar™. Complete target wound closure is defined as skin re-epithelialization without drainage BSAi of lesional skin: percentage of total body coverage of epidermolysis bullosa–related lesions (blisters, erosions, ulcerations, scabbing, bullae, and eschars, as well as areas that are weeping, sloughing, oozing, crusted, and/or denuded) BSAi of wound burden: percentage of total body coverage of epidermolysis bullosa wounds, defined as open areas on the skin (epidermal covering is disrupted) Itch, using the Itch Man Pruritus Assessment Tool10 Pain, using the Face, Legs, Activity, Cry, Consolability (FLACC) scale for patients aged 1 month to 3 years and the Wong-Baker FACES® Pain Scale for patients aged 4 years. Each of the 5 categories in the FLACC scale is scored from 0 to 2, with a cumulative score ranging from 0-10. The Wong-Baker FACES® Pain Scale also ranges from 0 to 10. Higher scores indicate greater pain11,12 •   Often diagnosed in neonates; occurs in 19 per million live births in the United States as estimated from the National Epidermolysis Bullosa Registry, a cross-sectional and longitudinal epidemiologic study of patients with epidermolysis bullosa across the continental United States2 Subtypes differ by physical manifestations, genetic makeup, and prognosis2 Symptoms (blistering, scarring, disfiguration, pain) can vary in severity and may lead to premature death as well as major morbidities, including life-threatening infections, sepsis, and squamous cell carcinoma1,3-6  Wong-Baker FACES® Pain Scale (age 4 years) Mean ± standard deviation Median (min, max) 102/104 3.2 ± 2.7 4.0 (0.0, 10.0) Both pain scales range from 0-10, with higher scores indicating greater pain. FLACC=Face, Legs, Activity, Cry, Consolability; n/N=number of patients included in analysis/number of patients eligible for assessment. • The medical history of patients enrolled in ESSENCE varied, with the most commonly recorded medical conditions at baseline being pruritus and pain (Table 3) • SD-101 is a novel, proprietary, topical, allantoin-containing cream under investigation in clinical trials as a potential treatment for skin lesions associated with epidermolysis bullosa7,8 In 2013, SD-101 became one of the first drug candidates to receive Breakthrough Therapy designation from the US Food and Drug Administration for the treatment of patients with epidermolysis bullosa7,8 The efficacy and safety of SD-101 has been investigated in SD-003, a phase 2b, multicenter, randomized, double-blind, vehicle-controlled, dose-ranging, 3-month study (NCT02014376)4 Table 3. Medical History by System Organ Class Reported in At Least 20% of Patients • BASELINE RESULTS As of February 21, 2017, ESSENCE was enrolling patients worldwide and included patients with a wide variety of ages and all major types of epidermolysis bullosa (Table 1 and Figure 2) • • Treatment with SD-101 cream containing 6% allantoin (SD-101 6%) demonstrated a higher rate of wound closure in patients with epidermolysis bullosa relative to treatment with vehicle SD-101 6% was generally safe and well tolerated in patients with epidermolysis bullosa Skin and subcutaneous tissue disorders Pruritus 79 (62.7) 63 (50.0) Table 1. ESSENCE Baseline Demographics and Characteristics, as of February 2017 Infections and infestations 56 (44.4) OBJECTIVE To describe the baseline characteristics of patients with epidermolysis bullosa enrolled in the ongoing ESSENCE trial as of February 2017 Blood and lymphatic system disorders 50 (39.7) • Injuries, poisonings, and procedural complications 30 (23.8) METHODS ESSENCE (SD-005; NCT02384460) is a phase 3, multicenter, randomized, double-blind, vehicle-controlled, ongoing study to assess the efficacy and safety of SD-101 6% vs vehicle (SD-101 0%) on lesions in patients with simplex, recessive dystrophic, or junctional non-Herlitz epidermolysis bullosa9 (Figure 1) Male 59 (46.8) Congenital, familial, and genetic disorders 28 (22.2) • Data reported as n (%). CONCLUSIONS The two primary endpoints are time to complete target wound closure and proportion of patients with complete target wound closure Secondary endpoints include change in body surface area index (BSAi) of lesions and blisters, patient-reported itching, and patient-reported pain Epidermolysis bullosa subtype Simplex Recessive dystrophic Junctional non-Herlitz 14 (11.1) 85 (67.5) 27 (21.4) Figure 1. ESSENCE Study Design 2 All patients (n=125) 17.4 ± 4.4 REFERENCES El Hachem M et al. Orphanet J Rare Dis. 2014;9:76. Fine J-D. Orphanet J Rare Dis. 2010:5;12. Pagliarello C, Tabolli S. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):329-338. Brandling-Bennett HA, Morel KD. Pediatr Dermatol. 2010;27(1):25-28. Mellerio JE et al. Br J Dermatol. 2016;174(1):56-67. Montaudié H et al. Orphanet J Rare Dis. 2016;11(1):117. Paller A et al. Presented at: 42nd Annual Meeting of the Society for Pediatric Dermatology; July 14-17, 2016; Minneapolis, MN. Aggarwal SR. Nature Biotechnol. 2014;32(4):323-330. ClinicalTrials.gov Web site. https://clinicaltrials.gov/ct2/show/NCT02384460. Accessed April 19, 2017. Morris V et al. J Burn Care Res. 2012;33(3):419-424. Merkel SI et al. Pediatr Nurs. 1997;23(3):293-797. Wong DL et al, eds. Wong’s Essentials of Pediatric Nursing. 6th ed. St. Louis, MO: Mosby; 2001. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. BSAi of lesional skin, % All patients (n=124) Age >1 month to <8 years (n=42) Age 8 years (n=82) 24.4 ± 19.4 15.6 ± 14.8 28.9 ± 20.0 ACKNOWLEDGMENTS The authors acknowledge the patients, their families, and epidermolysis bullosa patient organizations, as well as the ESSENCE study investigators. Third-party medical writing assistance was provided by ApotheCom and was supported by Amicus Therapeutics, Inc. ESSENCE was initiated in Q2 of 2015, and topline results are expected in Q3 of 2017. Q=quarter. Target wound size, cm2 21.67 ± 27.5 Numbers reported as mean ± standard deviation (min, max) or n (%). The number of patients included in each analysis is noted if data were not available for all 126 patients. BSAi=body surface area index; N/A=not applicable. Key Inclusion Criteria • • • Diagnosis of simplex, recessive dystrophic, or junctional non-Herlitz epidermolysis bullosa Age 1 month Target wound 21 days old and between 10 and 50 cm2 in size Figure 2. Country Enrollment, as of February 2017 (N=126) DISCLOSURE Key Exclusion Criteria • • • Clinical evidence of local infection in the selected target wound Use of immunotherapy or cytotoxic chemotherapy 60 days before enrollment Use of any investigational drug or systemic or topical steroidal therapy 30 days before enrollment (inhaled steroids and ophthalmic drops containing steroids are allowed) Use of systemic antibiotics 7 days before enrollment Arterial or venous disorder resulting in ulcerated lesions Conflicts of Interest JB is an investigator and conducts clinical research for Amicus Therapeutics, Galderma, Valeant, Patagonia, and Regeneron, and is a speaker for Medimetriks and Promius. AB is a consultant and investigator and conducts clinical research for Amicus Therapeutics and Scioderm - An Amicus Therapeutics Company, and serves on advisory boards for Anacor and Pfizer. RC is an investigator for Scioderm - An Amicus Therapeutics Company and Amicus Therapeutics. AL-S is an investigator for • • Scioderm - An Amicus Therapeutics Company. AP is a consultant and investigator for Amicus Therapeutics. HL, AR, and RL are employees of and own stock in Amicus Therapeutics. JG, WL, LR, and RN are employees of Scioderm - An Amicus Therapeutics Company and own stock in Amicus Therapeutics. Application • SD-101 6% or vehicle is applied topically once daily to the entire body as a thin layer for a period of 90 days. Patients/parents are taught how to apply the cream at first visit http://bit.ly/2958kHL Supported by Amicus Therapeutics, Inc. Presented at the 76th Annual Meeting of the Society for Investigative Dermatology; April 26-29, 2017; Portland, OR, USA 2% 1% 1% 4% 4% 6% United States (n=55) Germany (n=14) Italy (n=8) Spain (n=5) 6% Netherlands (n=3) Lithuania (n=1) 44% France (n=18) Australia (n=8) 6% Poland (n=8) United Kingdom (n=5) Austria (n=1) 11% 14% BSAi of wound burden, % All patients (n=124) 10.8 ± 11.0 Age >1 month to <8 years (n=42) 8.9 ± 11.5 Age 8 years (n=82) 11.9 ± 10.6 Body mass index, kg/m Age >1 to 24 months (n=17) 16.5 ± 4.2 Age >24 months to 12 years (n=57) 15.6 ± 3.7 Age >12 to 18 years (n=15) 16.7 ± 3.3 Age >18 to 65 years (n=35) 20.9 ± 4.2 Age >65 years (n=1) 20.1 ± N/A Days 1 14 30 60 90 Baseline Visit Target wound selection 10-50 cm2 21 days old Safety and Efficacy Assessment Visits SD-101 6% Optional open-label extension NCT02670330 Daily whole-body application of cream Vehicle SD-101 6% Patients with epidermolysis bullosa Age: 1 month (N150) Randomized 1:1 • ESSENCE is one of the largest clinical trials of an investigational drug conducted in patients with epidermolysis bullosa • Patients enrolled thus far have substantial pain burden and large chronic wounds, and represent a range of disease severity (both in epidermolysis bullosa type and extent of body coverage of epidermolysis bullosa lesions), ages, and geographic distribution • Top-line results for the phase 3 ESSENCE study are expected in Q3 of 2017 Race Black/African American 7 (5.6) Asian 8 (6.3) White 105 (83.3) Unknown 5 (4.0) Mixed 1 (0.8) Eye disorders 29 (23.0) Metabolism and nutrition disorders 50 (39.7) Surgical and medical procedures 54 (42.9) General disorders and administration-site conditions 69 (54.8) Pain 63 (50.0) Baseline Total (N=126) Age All patients, years (range) 15.1 ± 14.3 (0, 67) 0 to 1 month 0 (0) >1 to 24 months 17 (13.5) >24 months to 12 years 58 (46.0) >12 to 18 years 15 (11.9) >18 to 65 years 35 (27.8) >65 years 1 (0.8) System Organ Class and Medical Condition Total (N=126) Gastrointestinal disorders 83 (65.9) Constipation 55 (43.7) Gastro-oesophageal reflux disease 26 (20.6) Pain Assessment n/N Baseline FLACC scale (age >1 month to 3 years) 15/22 Mean ± standard deviation Median (min, max) 3.9 ± 2.1 4.0 (1.0, 9.0)